Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days.

Trial Profile

Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Tripotassium dicitrato bismuthate/tetracycline/metronidazole (Primary) ; Amoxicillin; Clarithromycin; Omeprazole
  • Indications Gastro-oesophageal reflux; Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Aptalis
  • Most Recent Events

    • 15 Mar 2012 This trial has been recruiting in France, United Kingdom and Spain and completed in Netherlands, Poland, Ireland and Italy.
    • 22 Feb 2011 Primary endpoint 'Helicobacter-pylori-eradication-rate' has been met, based on results published in Lancet.
    • 02 May 2010 Results were presented at Digestive Disease Week 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top